[{"id":"0b459d07-ccf7-4abe-b4b8-9e5eeb0622f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04260945","created_at":"2021-01-18T20:42:22.444Z","updated_at":"2024-07-02T16:36:15.885Z","phase":"Phase 1","brief_title":"CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients","source_id_and_acronym":"NCT04260945","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 positive • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • YTS101"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/10/2020","start_date":" 03/10/2020","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2022-03-08"},{"id":"451c4f4b-9465-4554-afdf-32dc3a696467","acronym":"","url":"https://clinicaltrials.gov/study/NCT04260932","created_at":"2021-01-18T20:42:22.025Z","updated_at":"2024-07-02T16:36:15.890Z","phase":"Phase 1","brief_title":"CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients","source_id_and_acronym":"NCT04260932","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 positive • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • YTS101"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 05/10/2021","primary_completion_date":" 05/10/2021","study_txt":" Completion: 09/10/2021","study_completion_date":" 09/10/2021","last_update_posted":"2022-03-08"},{"id":"274580fe-a4e0-4512-88bb-8ac1dcaafb4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697290","created_at":"2021-01-19T20:49:49.348Z","updated_at":"2024-07-02T16:36:17.180Z","phase":"Phase 1","brief_title":"CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.","source_id_and_acronym":"NCT04697290","lead_sponsor":"Beijing Tsinghua Chang Gung Hospital","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 positive • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • YTS101"],"overall_status":"Suspended","enrollment":" Enrollment 12","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 06/10/2023","study_completion_date":" 06/10/2023","last_update_posted":"2022-02-14"}]